2012 Scrip 100: Working the biosimilar boom
This article was originally published in Scrip
As the next wave of patent cliff expirations erode into the balance sheets of the largest healthcare firms, biosimilar manufacturers will be handed huge opportunities. However, there are still many grey clouds hanging over the manufacture of biosimilars, both in terms of legislation and commercialisation. Maribel Rios of BioProcess International looks into this complex topic.
Register for our free email digests: